Rhinosinusitis Chronic Clinical Trial
Official title:
Effects of Osteopathic Manipulative Treatment in Chronic Non-allergic Rhinosinusitis: a Randomised Placebo-controlled Trial
Verified date | July 2023 |
Source | Institut des Hautes Etudes Osteopathiques de Nantes |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chronic Rhinosinusitis (CRS) is a chronic condition with limited therapeutic options. Moreover, the pathophysiology is poorly understood. The aim of this study is to evaluate the efficacy of osteopathic manipulative treatment (OMT) in the course of this condition by applying several techniques supposed to be related to the autonomic nervous system. Our hypothesis is that these techniques could have beneficial effects on inflammation and head symptoms in CRS. Methods: A sample of 90 patients diagnosed by ENT specialist will be randomly assigned to the OMT group or the placebo group. The placebo procedure will consist in using light touch around the nose, on the throat and on the thorax. Treatment and placebo protocols are composed of two visits at day 0 and day 30. A general practitioner will determine the eligibility for the study. The outcomes include Peak Nasal Inspiratory Flow (PNIF) measured five times: at day 0, 30 (twice each, before and after treatment) and 180 (once). The two groups will be compared regarding short and long term evolution. The evolution of symptoms will be assessed by the Sino-nasal Outcome Test (SNOT-22) seven times: at day 0, 30, 60, 90, 120, 150 and 180. This outcome will be analyzed using mixed effect modelling A Qualitative study will be conducted in the two groups to understand the patients' experiences during care. This protocol has been approved by a french ethic committee (Comité de Protection des Personnes Sud Ouest et Outre-Mer II, 2020.04.09).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 30, 2022 |
Est. primary completion date | June 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - age between 18 and 50 - Chronic rhinosinusitis diagnosed by ear, nose, and throat (ENT) specialist or general practitioner - informed consent given - registered under french social security system Exclusion Criteria: - contraindication to spine manipulation - receiving other treatment for CRS during this study - being pregnant - being under legal protection - withdrawal of consent |
Country | Name | City | State |
---|---|---|---|
France | Cabinet ORL du Maine | Le Mans |
Lead Sponsor | Collaborator |
---|---|
Institut des Hautes Etudes Osteopathiques de Nantes |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in peak nasal inspiratory flow (PNIF) | The aim of this outcome is to measure change in nasal airflow during maximal inspiration with a facial mask. | PNIF will be perform at day 0 (before treatment) and at day 30 (before treatment) | |
Secondary | Change in Sino-nasal Outcomes Test 22 (SNOT-22) | This is a symptom-based rhinosinusitis questionnaire. Possible total scores range from 0 to 110, where a higher score indicates worse symptoms. | Patients will complete the questionnaire at baseline (day 0), day 30, day 60, day 90, day 120, day 150 and day 180 to assess the change over time | |
Secondary | Patient-reported experience of care | Individual interviews will enable to document the personal experience during effective or placebo treatment. | Interview will occur at day 180 | |
Secondary | Sort term change in peak nasal inspiratory flow (PNIF) | The aim of this outcome is to measure change before and after each treatment in nasal airflow during maximal inspiration with a facial mask. | PNIF will be perform at day 0 (before and after treatment), day 30 (before and after treatment) | |
Secondary | long term change in peak nasal inspiratory flow (PNIF) | The aim of this outcome is to measure change in nasal airflow during maximal inspiration with a facial mask from base line to day 180. | PNIF will be perform at day 0 (before treatment) and at day 180. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05923047 -
Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study.
|
Phase 4 | |
Not yet recruiting |
NCT05836935 -
Role of Imaging in Complications of Sinusitis
|
N/A | |
Not yet recruiting |
NCT05167552 -
Treatment of Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells
|
Phase 1/Phase 2 | |
Completed |
NCT04703673 -
Sinolpan® Pharmacy Non-interventional Study - Quality of Live
|
||
Recruiting |
NCT05639686 -
TIVA vs TXA in Sinus Surgery to Evaluate Operative Blood Loss and Surgical Field Quality
|
N/A | |
Recruiting |
NCT05015530 -
Impact of Symbiofilm On Nasal Microbiota
|
||
Not yet recruiting |
NCT06105346 -
Prevalence of ENT Diseseas
|
||
Recruiting |
NCT05450471 -
Effectiveness of Endonasal Polymeric Implant for Chronic Rhinosinusitis
|
Phase 3 | |
Terminated |
NCT03675022 -
Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis
|
Early Phase 1 |